Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

PHASE4CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

December 2, 2004

Primary Completion Date

September 6, 2005

Study Completion Date

September 6, 2005

Conditions
Postmenopausal Symptoms
Interventions
DRUG

Estrogel

OTHER

Placebo

Trial Locations (109)

Unknown

Site 112, Birmingham

Site 74, Mobile

Site 20, Montgomery

Site 34, Tucson

Site 68, Tucson

Site 5, Jonesboro

Site 88, Little Rock

Site 95, Little Rock

Site 104, Carmichael

Site 42, Encinitas

Site 21, San Diego

Site 37, San Diego

Site 78, San Diego

Site 82, San Diego

Site 69, Avon

Site 58, Bridgeport

Site 3, Groton

Site 72, Hartford

Site 54, New Britain

Site 79, Southport

Site 18, Waterbury

Site 97, West Hartford

Site 35, Aventura

Site 36, Aventura

Site 105, Clearwater

Site 49, Clearwater

Site 91, Daytona Beach

Site 57, Melbourne

Site 109, Miami

Site 39, Pinellas Park

Site 107, Spring Hill

Site 100, Tampa

Site 77, West Palm Beach

Site 61, Alpharetta

Site 81, Alpharetta

Site 28, Atlanta

Site 93, Atlanta

Site 55, Decatur

Site 13, Douglasville

Site 87, Powder Springs

Site 22, Savannah

Site 99, Savannah

Site 53, Boise

Site 96, Champaign

Site 24, Chicago

Site 84, Chicago

Site 26, Peoria

Site 46, Peoria

Site 75, Evansville

Site 45, South Bend

Site 8, Waterloo

Site 108, Lexington

Site 50, Baton Rouge

Site 12, Metairie

Site 65, New Orleans

Site 16, Shreveport

Site 11, Baltimore

Site 66, Ann Arbor

Site 15, Chaska

Site 29, Creve Coeur

Site 2, St Louis

Site 67, St Louis

Site 19, Billings

Site 56, Lincoln

Site 6, Las Vegas

Site 40, Reno

Site102, Olean

Site 31, Fayetteville

Site 60, New Bern

Site 59, Raleigh

Site 38, Winston-Salem

Site 70, Winston-Salem

Site 85, Winston-Salem

Site 86, Cincinnati

Site 101, Edmond

Site 89, Eugene

Site 111, Medford

Site 64, Portland

Site 113, Erie

Site 98, Pottstown

Site 33, Greenville

Site 9, Chattanooga

Site 92, Memphis

Site 76, Nashville

Site 83, Carrollton

Site 17, Conroe

Site 23, Corpus Christi

Site 25, Corpus Christi

Site 30, Dallas

Site 90, Dallas

Site 10, Houston

Site 110, Houston

Site 14, Houston

Site 27, Houston

Site 48, Houston

Site 51, Houston

Site 71, Houston

Site 73, Houston

Site 43, San Antonio

Site 62, San Antonio

Site 80, San Antonio

Site 7, Texarkana

Site 44, Salt Lake City

Site 94, Salt Lake City

Site 47, Norfolk

Site 106, Richmond

Site 41, Richmond

Site 4, Seattle

Site 52, Tacoma

Sponsors
All Listed Sponsors
collaborator

Solvay Pharmaceuticals

INDUSTRY

lead

ASCEND Therapeutics

INDUSTRY

NCT00160173 - Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy | Biotech Hunter | Biotech Hunter